Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Several other research firms also recently weighed in on ANIX. Maxim Group initiated coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They issued a "buy" rating and a $10.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, March 25th.

Anixa Biosciences Trading Down 3.6 %

ANIX stock traded down $0.11 during midday trading on Wednesday, hitting $2.97. 81,233 shares of the company's stock were exchanged, compared to its average volume of 97,441. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The stock has a market capitalization of $95.63 million, a PE ratio of -7.62 and a beta of 0.86. The business has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.00.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). As a group, research analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In related news, CEO Amit Kumar acquired 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the completion of the transaction, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the acquisition, the director now owns 922,334 shares of the company's stock, valued at $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 75,289 shares of company stock valued at $177,021 in the last 90 days. Company insiders own 25.30% of the company's stock.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in shares of Anixa Biosciences in the 4th quarter valued at about $26,000. Focus Partners Wealth purchased a new position in Anixa Biosciences in the fourth quarter valued at approximately $162,000. Jane Street Group LLC acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $67,000. Renaissance Technologies LLC raised its holdings in Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after purchasing an additional 3,900 shares in the last quarter. Finally, LPL Financial LLC lifted its position in shares of Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after buying an additional 11,633 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.